Standard BioTools, Inc. (LAB)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$0.69+1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · LAB
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-13.3) + peer(0.2*7.1) + term(0.0) → -3.24% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition On August 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2026. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statem…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition On May 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2026. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement discla…
Results of Operations and Financial Condition On February 24, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward…
Results of Operations and Financial Condition. On January 30, 2026, the Company issued a press release (the “Press Release”), as described further under
Results of Operations and Financial Condition On January 8, 2026, Standard BioTools Inc. (the "Company") issued a press release, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company's preliminary financial results are unaudited and based on current expectations and may be adjusted as a re…
Results of Operations and Financial Condition On November 4, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and nine months ended September 30, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Operational Restructuring,” “Full Year 2025 Revenue Outlook” and “About Standard BioTools Inc.,” tog…
Results of Operations and Financial Condition On August 11, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forw…
Results of Operations and Financial Condition On May 6, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forward-looking…
Results of Operations and Financial Condition On February 26, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together…
Results of Operations and Financial Condition. On January 13, 2025, Standard BioTools Inc. (the “Company”) issued a press release and updated its investor presentation, as described further below, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2024. The press release and investor presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference.…
Results of Operations and Financial Condition On October 30, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and nine months ended September 30, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “FY 2024 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forw…
Results of Operations and Financial Condition On July 31, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Updated FY 2024 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forwa…
Results of Operations and Financial Condition On May 8, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Outlook for 2024” and under the heading “About Standard BioTools Inc.,” together with the forward-looking statement dis…
Results of Operations and Financial Condition On February 28, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2023. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Outlook for 2024” and under the heading “About Standard BioTools Inc.,” together with the forw…
Results of Operations and Financial Condition. On January 8, 2024, Standard BioTools Inc. (the “Company”) issued a press release which included information with respect to certain preliminary financial results of the Company and SomaLogic, Inc. for the three months and fiscal year ended December 31, 2023. The press release is attached hereto as Exhibits 99.1 and incorporated herein by reference.